Clinical Analysis of Peripheral Blood Indicators for Immune-Related Adverse Events (irAEs) in Patients With Advanced Lung Cancer.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs) have revolutionized advanced lung cancer treatment, but immune-related adverse events (irAEs) remain a significant challenge. This study aimed to identify peripheral blood indicators associated with Immune-Related Adverse Events (irAEs) to improve early prediction and management.

Methods

A retrospective analysis of 1910 advanced lung cancer cases treated with ICIs (2015-2024) was conducted. Patients were categorized into 2 groups: irAEs (n = 323) and control (n = 323). Peripheral blood indicators were analyzed at baseline and during treatment. Statistical analyses included t-tests, Mann-Whitney U tests, logistic regression, and Cox proportional hazards models.

Results

Age (odds ratio [OR] = 0.96, P < .001) and radi

SUBMITTER: Ji YM 

PROVIDER: S-EPMC12819973 | biostudies-literature | 2026

REPOSITORIES: biostudies-literature